SCHEMBL221209

SCHEMBL221209

Nc1cc(Br)nc(Br)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14920610 0.81
SCHEMBL1755602 0.81
SCHEMBL16992913 0.81
SCHEMBL28633047 0.81
SCHEMBL29879751 0.81
SCHEMBL2036018 0.79 ALDH1A1 (0.40)
SCHEMBL8539457 0.76 ALDH1A1 (0.46)
SCHEMBL24739800 0.75 HTR6 (0.32)
SCHEMBL17449306 0.75 HTT (0.34)
SCHEMBL5865115 0.75 NOS3 (0.45)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115403562-A 2',6' -di-2- (1-hydrogen imidazolyl) -4-halogenated pyridine compound and preparation method and application thereof 深圳大学 2022-11-29 CN claimed
CN-111317721-B Nano drug-loaded drug release system, application and preparation method thereof, and preparation method of 2, 6-diphenylpyridine derivative 深圳金普迈生物科技有限公司 2022-05-17 CN claimed
CN-111317721-A Nano drug-loaded drug release system, application and preparation method thereof, and preparation method of 2, 6-diphenylpyridine derivative 深圳金普迈生物科技有限公司 2020-06-23 CN claimed
EP-4743456-A1 COMPOUNDS, PREPARATION METHODS AND USES THEREOF InventisBio Co., Ltd. (CN) 2026-05-20 EP disclosed
EP-4658647-A1 TRICYCLIC AZEPINONE DERIVATIVES AS SYSTEM XC INHIBITORS UCB Biopharma SRL (BE) 2025-12-10 EP disclosed
EP-4585265-A2 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN Takeda Pharmaceutical Company Limited (JP) 2025-07-16 EP disclosed
WO-2025137293-A2 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS Roche Sequencing Solutions, Inc. (US) 2025-06-26 WO disclosed
CN-119823106-A Enhanced nucleic acid polymerization by aromatic compounds 豪夫迈·罗氏有限公司 2025-04-15 CN disclosed
US-20250075265-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS ROCHE SEQUENCING SOLUTIONS INC (US) 2025-03-06 US disclosed
WO-2025016314-A1 COMPOUNDS, PREPARATION METHODS AND USES THEREOF InventisBio Co., Ltd. (CN) 2025-01-23 WO disclosed
EP-4490159-A1 TRICYCLIC HETEROCYCLE COMPOUNDS AS IAP ANTAGONISTS Ascentage Pharma (Suzhou) Co., Ltd. (CN) 2025-01-15 EP disclosed
US-6030976-A SELECTIVE AFFINITY TO 5HT-6 RECEPTORS; CENTRAL NERVOUS SYSTEM DISORDERS; ALZHEIMER'S DISEASE, PSYCHOSES, SCHIZOPHRENIA, MANIC DEPRESSIONS, MEMORY DISORDERS, PARKINSON'S DISEASE, AMYOTROPHIC LATERAL SCLEROSIS AND HUNTINGTON'S DISEASE HOFFMAN-LA ROCHE INC. (US) 2000-02-29 US disclosed
US-5998665-A THERAPY FOR NERVOUS SYSTEM DISORDERS HOFFMANN-LA ROCHE INC. (US) 1999-12-07 US disclosed
US-5939451-A INDOL-4-YL-BENZENESULFONAMIDES AS ACTIVE MATERIAL TREATING MALARIA, BACTERIAL INFECTION, NEUROLOGICAL DISORDERS HOFFMANN-LA ROCHE INC. (US) 1999-08-17 US disclosed
US-5932599-A 4-AMINO-N-(PYRIDINYL-4-YL)-BENZENESULFONAMIDES AS ACTIVE MATERIAL TREATING MALARIA, BACTERIAL INFECTION, NEUROLOGICAL DISORDERS HOFFMANN-LA ROCHE INC. (US) 1999-08-03 US disclosed
US-5929082-A SULFONYL(THIO)UREA AND SULFONYLGUANIDINE COMPOUNDS; TREATMENT OF DIABETES, CARDIAC ARRHYTHMIAS, ISCHEMIA, HYPOXIC CARDIOVASCUALR DISORDERS AND CANCER POLYCHIP PHARMACEUTICALS PTY LTD (AU) 1999-07-27 US disclosed
EP-0819118-A4 POTASSIUM ION CHANNEL BLOCKERS POLYCHIP PHARMACEUTICALS PTY (AU) 1998-04-29 EP disclosed
EP-0819118-A1 POTASSIUM ION CHANNEL BLOCKERS Polychip Pharmaceuticals Pty. Ltd. (AU) 1998-01-21 EP disclosed
EP-0815861-A1 Sulphonamides and their use F. HOFFMANN-LA ROCHE AG (CH) 1998-01-07 EP disclosed
WO-1996030341-A1 POTASSIUM ION CHANNEL BLOCKERS POLYCHIP PHARMACEUTICALS PTY. LTD. (AU) 1996-10-03 WO disclosed